Literature DB >> 21669939

The resveratrol analogue, 2,3',4,5'-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo[a]pyrene-DNA adduct formation in MCF-7 cells exposed to benzo[a]pyrene.

Tracey Einem Lindeman1, Miriam C Poirier, Rao L Divi.   

Abstract

Exposure to carcinogenic polycyclic aromatic hydrocarbons (PAHs) induces cytochrome P450 (CYP) 1A1 and 1B1 enzymes, which biotransform PAHs resulting in the formation of DNA adducts. We hypothesised that 2,3',4,5'-tetramethoxystilbene (TMS), an analogue of resveratrol and a potent CYP1B1 inhibitor, may inhibit r7, t8, t9-trihydroxy-c-10-(N(2)deoxyguanosyl)-7,8,9,10-tetrahydro-benzo[a]pyrene (BPdG) adduct formation in cells exposed to benzo[a]pyrene (BP). To address this, MCF-7 cells were cultured for 96 h in the presence of 1 μM BP, 1 μM BP + 1 μM TMS or 1 μM BP + 4 μM TMS. Cells were assayed at 2-12 h intervals for: BPdG adducts by r7, t8-dihydroxy-t-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE)-DNA chemiluminescence immunoassay; CYP1A1 and 1B1 gene expression changes by relative real-time polymerase chain reaction; and CYP1A1/1B1 enzyme activity by ethoxyresorufin-O-deethylase (EROD) assay. Whereas maximal BPdG levels were similar for all exposure groups, the times at which the maxima were reached increased by 16 and 24 h with the addition of 1 and 4 μM TMS, respectively. The maximal expression of CYP1A1 and CYP1B1 occurred at 16, 24 and 48 h, but the maximal level for EROD-specific activity was reached at 24, 48 and 60 h, in cells exposed to 1 μM BP, 1 μM BP + 1 μM TMS or 1 μM BP + 4 μM TMS, respectively. The area under the curve from 4 to 96 h of exposure (AUC(4-)(96 h)) for BPdG adduct formation was not increased in the presence of TMS, but for CYP1A1 and CYP1B1 expression fold increase AUC(4-)(96 h) and EROD-specific activity AUC(4-)(96 h), there were significant (P < 0.05) increases in the presence of 4 μM TMS. Therefore, during 96 h of exposure in MCF-7 cells, the combination of BP plus TMS caused a slowing of BP biotransformation, with an increase in CYP1A1 and CYP1B1 expression and EROD activity, and a slowing, but no change in magnitude of BPdG formation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21669939      PMCID: PMC3162036          DOI: 10.1093/mutage/ger024

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  39 in total

1.  Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  2010

2.  Genotoxic polycyclic aromatic hydrocarbon ortho-quinones generated by aldo-keto reductases induce CYP1A1 via nuclear translocation of the aryl hydrocarbon receptor.

Authors:  M E Burczynski; T M Penning
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  Benzo(a)pyrene diol epoxides as intermediates in nucleic acid binding in vitro and in vivo.

Authors:  I B Weinstein; A M Jeffrey; K W Jennette; S H Blobstein; R G Harvey; C Harris; H Autrup; H Kasai; K Nakanishi
Journal:  Science       Date:  1976-08-13       Impact factor: 47.728

Review 4.  Initiation of cancer and other diseases by catechol ortho-quinones: a unifying mechanism.

Authors:  E L Cavalieri; E G Rogan; D Chakravarti
Journal:  Cell Mol Life Sci       Date:  2002-04       Impact factor: 9.261

Review 5.  Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents.

Authors:  Young-Jin Chun; Sanghee Kim
Journal:  Med Res Rev       Date:  2003-11       Impact factor: 12.944

6.  Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells.

Authors:  Zhi-Hua Chen; Yeon-Jin Hurh; Hye-Kyung Na; Jung-Hwan Kim; Young-Jin Chun; Dong-Hyun Kim; Kyung-Sun Kang; Myung-Haing Cho; Young-Joon Surh
Journal:  Carcinogenesis       Date:  2004-05-13       Impact factor: 4.944

Review 7.  Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1.

Authors:  Tsutomu Shimada; Yoshiaki Fujii-Kuriyama
Journal:  Cancer Sci       Date:  2004-01       Impact factor: 6.716

8.  Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue.

Authors:  Dawn M Carnell; Rowena E Smith; Frances M Daley; Paul R Barber; Peter J Hoskin; George D Wilson; Graeme I Murray; Steven A Everett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-02-01       Impact factor: 7.038

Review 9.  Analysis of DNA and protein adducts of benzo[a]pyrene in human tissues using structure-specific methods.

Authors:  Gunnar Boysen; Stephen S Hecht
Journal:  Mutat Res       Date:  2003-01       Impact factor: 2.433

10.  Highly sensitive chemiluminescence immunoassay for benzo[a]pyrene-DNA adducts: validation by comparison with other methods, and use in human biomonitoring.

Authors:  Rao L Divi; Frederick A Beland; Peter P Fu; Linda S Von Tungeln; Bernadette Schoket; Johanna Eltz Camara; Monica Ghei; Nathaniel Rothman; Rashmi Sinha; Miriam C Poirier
Journal:  Carcinogenesis       Date:  2002-12       Impact factor: 4.944

View more
  2 in total

1.  Co-exposure to amorphous silica nanoparticles and benzo[a]pyrene at low level in human bronchial epithelial BEAS-2B cells.

Authors:  Jing Wu; Yanfeng Shi; Collins Otieno Asweto; Lin Feng; Xiaozhe Yang; Yannan Zhang; Hejing Hu; Junchao Duan; Zhiwei Sun
Journal:  Environ Sci Pollut Res Int       Date:  2016-09-03       Impact factor: 4.223

2.  Effects of benzo[a]pyrene exposure on human hepatocellular carcinoma cell angiogenesis, metastasis, and NF-κB signaling.

Authors:  Qian Ba; Junyang Li; Chao Huang; Hongling Qiu; Jingquan Li; Ruiai Chu; Wei Zhang; Dong Xie; Yongning Wu; Hui Wang
Journal:  Environ Health Perspect       Date:  2014-10-17       Impact factor: 9.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.